Clinical Trials
33 trialsNCT04784715 2026-05-22
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca
Phase 3 Active not recruiting
NCT05043090 2026-05-22
SAMETA
AstraZeneca
Phase 3 Active not recruiting
NCT05208047 2026-05-22
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc.
Phase 3 Active not recruiting
NCT05374512 2026-05-15
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
AstraZeneca
Phase 3 Active not recruiting
NCT05294172 2026-05-08
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT05104866 2026-05-05
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
AstraZeneca
Phase 3 Active not recruiting
NCT06745024 2026-05-04
Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT05352672 2026-04-22
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT04964934 2026-04-21
SERENA-6
AstraZeneca
Phase 3 Active not recruiting
NCT03525873 2026-04-15
A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT05261399 2026-04-06
SAFFRON
AstraZeneca
Phase 3 Active not recruiting
NCT04205812 2026-03-31
POD1UM-304
Incyte Corporation
Phase 3 Active not recruiting
NCT04318886 2026-03-13
Lay Coach-Led Early Palliative Care for Underserved Advanced Cancer Caregivers: The Project ENABLE Cornerstone RCT
University of Alabama at Birmingham
Phase 3 Active not recruiting
NCT04895358 2026-03-11
KEYNOTE-B49
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT01592968 2026-03-09
Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT05501886 2026-02-10
VIKTORIA-1
Celcuity Inc
Phase 3 Active not recruiting
NCT05169567 2026-01-16
postMONARCH
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03869892 2025-12-22
SOLSTICE
Servier
Phase 3 Active not recruiting
NCT05201547 2025-12-04
DOMENICA
ARCAGY/ GINECO GROUP
Phase 3 Active not recruiting
NCT01933932 2025-11-19
SELECT-1
AstraZeneca
Phase 3 Active not recruiting
NCT04711252 2025-10-14
SERENA-4
AstraZeneca
Phase 3 Active not recruiting
NCT04035486 2025-10-10
FLAURA2
AstraZeneca
Phase 3 Active not recruiting
NCT04365374 2025-10-07
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
GT Medical Technologies, Inc.
Phase 3 Active not recruiting
NCT03734029 2025-10-06
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Daiichi Sankyo
Phase 3 Active not recruiting
NCT04158362 2025-09-22
AMBRE
UNICANCER
Phase 3 Active not recruiting
NCT02194842 2025-09-19
PEACE III
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Active not recruiting
NCT03721341 2025-09-18
SABR-COMET 10
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 3 Active not recruiting
NCT04879368 2025-07-17
INTEGRATEIIb
Australasian Gastro-Intestinal Trials Group
Phase 3 Active not recruiting
NCT04975308 2025-07-11
EMBER-3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05288166 2025-06-27
CYCLONE 3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05348577 2025-01-27
CAPItello280
AstraZeneca
Phase 3 Active not recruiting
NCT04685135 2025-01-22
KRYSTAL-12
Mirati Therapeutics Inc.
Phase 3 Active not recruiting
NCT01442246 2024-09-19
Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.
UNICANCER
Phase 3 Active not recruiting